Aleksandr Aleksandrovich Lisitsyn

Aleksandr Aleksandrovich Lisitsyn

Auto-generated profile, based on publicly available information

Aleksandr Aleksandrovich Lisitsyn

North-Western State Medical University Named After I.I. Mechnikov

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LVLudmila I. Velikanova
Ludmila I. Velikanova
NVNatalia V. Vorokhobina
Natalia V. Vorokhobina
ZSZulfiya R. Shafigullina
Zulfiya R. Shafigullina
VKValentina Kalugina
Valentina Kalugina
EMEkaterina V. Malevanaya
Ekaterina V. Malevanaya
БОБуйнова Мария Олеговна
Буйнова Мария Олеговна
Background: Adrenocortical cancer (ACC) is a rare aggressive and rapidly metastatic disease. Early diagnosis of the disease and its metastatic stage are important for the choice of treatment strategy. Evaluation of urine steroid profiles (USP) by gas chromatography-mass spectrometry (GC-MS) is a highly sensitive and specific biomarker instrument that allows for differentiation between benign and malignant tumor and obvious prospects for the diagnosis in patients with adrenal incidentalomas. In our previous study we have found no difference in urine excretion of tetrahydro-11-deoxycortisole (THS), 5-ene-pregnenes and 3,16,20-pregnenetriol/3,16,20-pregnenetriol ratio (3,16,20-dP3/3,16,20-dP3) in patients with metastatic ACC in early postoperative period, compared to pre-operative parameters. We did not account for the disease stage and primary tumor size in that study in ACC patients. Aim: To identify specific characteristics of urine steroid metabolome by GC-MS in ACC IIV stages patients before surgery in order to detect early signs of metastases and the relationship between adrenal steroidogenesis abnormalities and disease stages. Materials and methods: We performed a retrospective analysis of the data from the study of USP in 59 ACC stage I-IV patients with L. M. Weiss score 3, according to pathological examination of the surgical samples. The Cushing syndrome was diagnosed by immunochemistry assay in 28 (47.6%) of ACC patients. Tumor staging was done according to ENSAT based on the results of imaging and postoperative histological reports. ENSAT I was diagnosed in 8 patients, ENSAT II in 26, ENSAT III in 14, ENSAT IV in 11 ACC patients. The control group included 28 healthy donors. USP was assessed by GC-MS before surgery with a gas chromatography-mass-spectrometer Shimadzu GCMS-ТQ8050. Results: The first variant of urinary steroid metabolome abnormalities with increased excretion of dehydroepiandrosterone (DHEA) and THS was found in 10 (90.9%) of ENSAT IV ACC patients and in 20 (50%) of ENSAT II + III patients. The fourth USP variant was characterized by no difference in androgen and THS urinary excretion from that in healthy individuals and was found in ACC ENSAT I patients. Only in ACC ENSAT I patients, there was an increase of pregnanediol (P2) urinary excretion and of the P2/pregnanetriol (P3) ratio, compared to those in healthy donors. ROC-analysis demonstrated that ТНS 867 mcg/24 hours, 3,16,20-dP3 300 mcg/24 hours and 3,16,20-dP3/3,16,20-dP3 1.6 cut-offs had a sensitivity and specificity of 100% for preoperative identification of ENSAT IV ACC patients before surgery and for early diagnosis of ACC metastases. There were positive correlations between 16-oxo-androstenediol, THS, and progestogens, as well as a negative correlation between 3,16,20-dP3/3,16,20-dP3 ratio and the disease stage. Conclusion: Urinary excretion of THS, DHEA and its metabolites, P2, 5-ene-pregnenes, and 3,16,20-dP3/3,16,20-dP3 ratio determined by GC-MS are important biochemical markers of ACC stages and can be used as ACC metastases prognostic markers.

19 November 2017 in Journal of Experimental and Clinical Surgery
Verified
Journal Article
Open access
PDF file
VZVyacheslav Petrovich Zemlyanoy
Vyacheslav Petrovich Zemlyanoy
ALAleksandr Aleksandrovich Lisitsyn
Aleksandr Aleksandrovich Lisitsyn
MNMikhail Mikhailovich Nakhumov
Mikhail Mikhailovich Nakhumov
ENEvgeniya Mikhailovna Nesvit
Evgeniya Mikhailovna Nesvit
НМНахумов Михаил Михайлович
Нахумов Михаил Михайлович
Introduction: Pheochromocytoma is one of representative of neuroendocrine tumors. According this fact, pheochromocytoma remains to evaluation for multiply endocrine neoplasia, especially if disease is bilateral. In this case, it is necessary to additionally carry out a genetic screening test. The aim of the study is to Improve diagnosis and treatment outcomes for patients with MEN syndrome. Materials and methods: The authors present a clinical case of a 37-year-old man diagnosed and treated for a bilateral pheochromocytoma. Results: The patient was diagnosed medullary thyroid cancer after successful bilateral adrenalectomy. The patient underwent thyroidectomy. A genetic research showed the T1900 mutation in the codon of 634 RET gene, which confirmed the presence of the patient MEN 2 syndrome. According to the high concordance of the mutated gene, patient's son was carried out to genetic examinations, which confirmed the presence of this mutation. The boy underwent thyroidectomy opportunely. Discussion: Due to primary oncological observation if the patient has pheochromacytoma, it is necessary to exclude MAN 2 syndrome both in the patient himself and his relatives. The safest and informative method is genetic research. Conclusion: presently a comprehensive examination of both the patient himself and his relatives is necessary for timely diagnosis and correct management of treatment patients with MEN 2 syndrome.

17 September 2024 in Science and Innovations in Medicine
Verified
Journal Article
Open access
ALAleksandr A. Lisitsyn
Aleksandr A. Lisitsyn
VZVyacheslav P. Zemlyanoi
Vyacheslav P. Zemlyanoi
MNMikhail M. Nakhumov
Mikhail M. Nakhumov
ZSZulfiya R. Shafigullina
Zulfiya R. Shafigullina
SSSergei B. Shustov
Sergei B. Shustov
IBIrina A. Bekhtereva
Irina A. Bekhtereva
Aim – to study the diagnostic possibilities of comparative selective venous blood sampling from the central adrenal vein in patients with primary hyperaldosteronism with combined autonomous cortisol secretion. Material and methods. The study included 7 patients with primary hyperaldosteronism with combined autonomous secretion of cortisol who were treated in the clinic from 2010 to 2019. Results. In 72 operated patients with primary hyperaldosteronism, 7 (9.7%) were diagnosed with autonomous secretion of cortisol. The frequency of discrepancy between the intrascopic picture and comparative selective blood sampling in patients with combined autonomous aldosterone-cortisol secretion was 57.1%. Performing comparative selective blood sampling in patients with Connshing syndrome makes it possible to establish the side of hyperproduction of aldosterone and cortisol in bilateral adrenal adenoma with unilateral hormone production. Postoperative adrenal insufficiency was observed in 28.6% of patients Connshing syndrome. Mixed adrenal adenomas can be a source of joint hypersecretion of aldosterone and cortisol. Conclusions. In all patients with primary hyperaldosteronism, it is necessary to exclude the joint autonomous production of cortisol, which allows for a correct assessment of the results of comparative selective blood sampling, with subsequent choice of the intervention side and predict the risk of postoperative adrenal insufficiency.

22 November 2025 in Kazan medical journal
Verified
Journal Article
Closed access
PDF file
ALAleksandr A. Lisitsyn
Aleksandr A. Lisitsyn
VZVyacheslav P. Zemlianoy
Vyacheslav P. Zemlianoy
VMVadim I. Mazurov
Vadim I. Mazurov
LVLudmila I. Velikanova
Ludmila I. Velikanova
IBIrina A. Bekhtereva
Irina A. Bekhtereva
ЗПЗемляной Вячеслав Петрович
Земляной Вячеслав Петрович
High-resolution imaging has increased the detection rate of adrenal gland neoplasms, necessitating changes in the management of patients with adrenal incidentalomas. Despite existing guidelines, the treatment strategy in patients with incidental adrenal gland neoplasms of 4 cm remains debatable. According to the updated EHS/ENSAT guidelines on incidentalomas (2023), benign neoplasms with ≤10 HU do not require further imaging examinations. For neoplasms of 4 cm with a native density of 11–20 HU, a follow-up examination after 12 months is recommended. This paper presents a clinical case of adrenocortical cancer with autonomous cortisol secretion, which originated from a nonfunctioning right adrenal gland neoplasm of 2 cm. The tumor was detected accidentally during abdominal and retroperitoneal ultrasound and computed tomography; however, malignant transformation did not occur until 11 years later. A comprehensive preoperative assessment, including biochemical and imaging examinations, confirmed that the patient was eligible for elective surgery. A pathological examination confirmed an oncocytic adrenocortical carcinoma (Ki-67: 40%).

1 June 2025 in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
Verified
Journal Article
Closed access
PDF file
VKValentina Kalugina
Valentina Kalugina
NVN. V. Vorokhobina
N. V. Vorokhobina
LVL. I. Velikanova
L. I. Velikanova
ZSZ. R. Shafigullina
Z. R. Shafigullina
EME. V. Malevanaya
E. V. Malevanaya
ALA. A. Lisitsyn
A. A. Lisitsyn
The results of experimental and clinical studies indicate the involvement of platelets in the process of progression of malignant tumors of different localizations. Studying the effect of corticosteroids on thrombopoiesis in patients with adrenal cortex tumors will allow us to expand our understanding of the pathogenesis of adrenocortical cancer. Twenty two patients with adrenal cortex neoplasms were examined: 11 individuals with adrenocortical cancer (ACC) and 11 ones with adrenocortical adenoma (ACA). The diagnosis was confirmed based on the results of histological examination using the scale of L.M. Weiss. The age of patients was 58 (49–63) years, 5 (23%) of men were included in the study. No differences in the age, gender, or body mass index value between examined individuals with ACC and ACA were detected. In the preoperative period, all patients underwent clinical blood test with determination of leukocyte formula, calculation of systemic immune inflammation index (SII), urine steroid profiles were studied using gas chromatography/mass spectrometry. A larger number of platelets were obtained in ACC patients as compared with examined individuals with ACA: 282 (256‒310) × 109 and 222 (194‒251) × 109, р = 0.004. A lower SII value was detected in ACA patients as compared with ACC patients: 251 (186–354) and 618 (500–703), р = 0.002. Using gas chromatography/mass spectrometry method, higher urinary excretion of glucocorticoid metabolite tetrahydro-11-deoxycortisol, as well as androgens—dehydroepiandrosterone (DHEA) and etiocholanolone (Et) and 11β-OH-androsterone (androstenedione metabolites), progestogens—17-OH-pregnanolone, pregnanediol, pregnanetriol, pregnenediol, was demonstrated in ACC patients as compared with indices in ACA patients (p < 0.007). A linear dependence of the number of blood platelets on urinary excretion of Et (r = 0.81, p < 0.001) and DHEA (r = 0.94, p < 0.001), as well as SII on urinary excretion of DHEA (r = 0.90, p < 0.001), was demonstrated in all examined individuals.

30 June 2025 in HERALD of North-Western State Medical University named after I.I. Mechnikov
Verified
Journal Article
Closed access
PDF file
ALAleksandr A. Lisitsyn
Aleksandr A. Lisitsyn
LVLudmila I. Velikanova
Ludmila I. Velikanova
NVNatalia V. Vorokhobina
Natalia V. Vorokhobina
ZSZulfiya R. Shafigullina
Zulfiya R. Shafigullina
EMEkaterina V. Malevanaya
Ekaterina V. Malevanaya
ВВВорохобина Наталья Владимировна
Ворохобина Наталья Владимировна
BACKGROUND: The selection of surgical strategies for large adrenal tumors remains clinically critical. For determining eligibility for endoscopic video-assisted surgery, the absence of malignancy features is essential. Steroid metabolome analysis by gas chromatography-mass spectrometry (GC-MS) provides the highest diagnostic yield for detecting early signs of malignancy during preoperative evaluation and, according to multiple studies, exceeds the accuracy of radiologic imaging techniques. AIM: To evaluate the clinical utility of urine steroid profiling by GC-MS for preoperative diagnosis and surgical decision-making in large malignant adrenocortical neoplasms. METHODS: Patients with adrenal tumors larger than 50 mm and without clinical or laboratory signs of hypercortisolism were examined. Based on histological analysis, the following diagnoses were established: adrenocortical carcinoma, adrenocortical adenoma (with malignancy grade assessed using the Weiss scoring system), and rare adrenal diseases (schwannoma, ganglioneuroma, myelolipoma, etc.). Patients with adrenocortical adenomas smaller than 50 mm served as the control group. Urinary steroid profiles were analyzed by gas chromatography-mass spectrometry in all patients before surgical treatment. The Mann-Whitney U test was used for comparison of urinary steroid excretion. RESULTS: According to gas chromatography-mass spectrometry (GC-MS), 23 patients (33.8%) with adrenal tumors 50 mm exhibited biochemical features of adrenocortical carcinoma (ACC) prior to surgery, which was later confirmed histologically. In patients with adrenocortical adenoma and a malignancy score of 2 on the Weiss scale (n = 16, 23.5%), urinary excretion of tetrahydro-11-deoxycortisol, androgens, progestogens, and mineralocorticoids was significantly higher than in patients with adrenocortical adenoma lacking malignant features (n = 14) and the control group (n = 30). No statistically significant differences were observed in the urinary excretion of 9 ACC biomarkers compared to patients with confirmed ACC. Open adrenalectomy was recommended for patients with large adrenal tumors and GC-MS evidence of malignancy. CONCLUSION: Preoperative GC-MS detection of early malignant features in large adrenal tumors is critical for determining the optimal surgical approach. Minimally invasive adrenalectomy is not recommended for large adrenal lesions with GC-MS signs of malignancy.